Shares of several gene-editing therapy developers rose during the past week as investors responded to data presented at the European Society of Gene and Cell Therapy’s 33rd Annual Congress and new draft guidance from the U.S. Food and Drug Administration on individualized genome-editing products.
The FDA issued the draft guidance on October 27. The document outlines a regulatory framework for submitting and managing Biologics License Applications for personalized gene therapies intended for patients with rare genetic diseases. It introduces the concept of an Individualized Feature Space, which would define the permitted range of variation for genome-editing components within a single application.
Under the proposed approach, therapies could be adapted for individual patients without requiring a separate clinical trial for every variation, provided the changes remain within the predefined limits. The FDA is accepting public comments through November 27.
FDA acting commissioner Kyle Diamantas described the framework as a response to the need for individualized treatment approaches in rare diseases. Jefferies analyst Maury Raycroft also characterized the draft guidance positively, citing its potential to support future regulatory milestones for gene-editing companies.
Prime Medicine posted the strongest weekly gain among the companies covered, with its shares increasing 29%, from $3.67 to $4.72. The stock had reached $5.91 during the week, although it remained below its 52-week high at Friday’s close.
Prime’s recent momentum has followed regulatory and clinical developments involving its in vivo prime-editing programs. The FDA recently cleared the company to begin a planned Phase I/II trial of PM647 in alpha-1 antitrypsin deficiency. Prime also dosed the first participant in a Phase I/II study of PM577a for Wilson disease involving the H1069Q mutation. The company expects initial data from that trial in 2027.
Beam Therapeutics gained 13%, rising from $24.05 to $27.23. The company reported initial data from its Phase I/II study of BEAM-301, a liver-targeting base-editing treatment for glycogen storage disease type Ia.
As of the August 17 data cutoff, two of three patients in the 40 mg cohort completed the trial’s maximum 15-hour controlled fasting period. Beam said those patients also achieved a complete reduction in daily starch requirements and showed improved glucose control. The third patient did not demonstrate an increase in time to fasting hypoglycemia, which the company linked potentially to body mass index and genetic factors.
Beam has begun enrolling a 60 mg cohort and plans to discuss a potential approval pathway with the FDA. Analysts cited the early results as encouraging, while noting that additional data will be needed to assess the program.
Editas Medicine shares rose 11%, from $2.40 to $2.67. At ESGCT, the company presented work on a scalable, targeted lipid-nanoparticle manufacturing platform and data showing delivery of messenger RNA to targeted T cells. The platform produced transient CAR expression and rapid depletion of B cells in blood, with additional depletion reported in lymphoid tissues.
Intellia Therapeutics also gained 11%, moving from $11.21 to $12.47. Investors are awaiting clinical data for lonvoguran ziclumeran, a one-time CRISPR/Cas9 treatment under development for hereditary angioedema. The data are scheduled for presentation at the American College of Allergy, Asthma & Immunology’s 2026 meeting from November 12 to 16 and will include four-year follow-up from patients who received a 50 mg dose.
Intellia executives and hereditary angioedema experts also plan to discuss preparations for a potential commercial launch during a November 12 conference call with analysts.
CRISPR Therapeutics rose 4%, from $49.39 to $51.42. Investors are awaiting the company’s third-quarter results and additional clinical updates, including a planned readout from a Phase Ib study of CTX310, an in vivo CRISPR/Cas9 candidate targeting ANGPTL3 in patients with severe hypertriglyceridemia. The data are scheduled for presentation at the American Heart Association’s 2026 Scientific Sessions from November 6 to 9.
The overall advance was not shared across the sector. Caribou Biosciences fell nearly 21%, from 53 cents to 42 cents, extending a decline associated with its review of strategic alternatives and plans to reduce a substantial portion of its workforce. The company’s shares had fallen 66% over the preceding month.
Market gains earlier in the week were moderated by a nearly 3% decline in the Nasdaq Composite on Friday following disappointing third-quarter results from technology and artificial-intelligence companies.